Deutsche Venture Capital

Panoratio was established in March, 2003, in Munich, Germany. The technology grew out of work started at the Siemens AG Artificial Intelligence / Machine Learning Laboratory to address optimization issues regarding the installation and performance of gas turbine engines within Siemens Westinghouse power plants.   While sensors placed throughout the power plant generated extremely complex datasets, it proved impossible to close the performance loop and analyze them efficiently. Researchers solved this problem by developing of a pure software solution that reduces the dataset's footprint without losing any of its granularity or complexity. Recognizing the universal value of the solution, Siemens AG, established Panoratio as a separate, independent entity.   Since then, Panoratio has developed PANOsight, a software suite underpinned by the patented compression technology, and has over 50 customers in production. The company is proud to count AOK, AOL, Avis, buch.de, InsightHealth, KarstadtQuelle, Macy's, SavaSeniorCare, Sierra Health Services, Siemens, Sixt, Vodafone and Yahoo! among them.

KeyNeurotek is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases.

MergeOptics GmbH, was founded in Germany, in September 2000. The company develops highly integrated components for the rapidly growing high-speed fiber optic data transfer market. The company integrates optical components (lasers, modulators and photo diodes) with high-frequency electrical circuits to create compact modules that operate with industry standard optical and electrical interfaces. MergeOptics' business objective is to specialize in high-speed optical products that are world-class for both integration and performance.   MergeOptics maintains partnerships with several leading German Universities and research facilities, including the prestigious Heinrich-Hertz-Fraunhofer Institute in Berlin, Germany.

VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators.   VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.

Apertio One provides a single, open, subscriber-centric architecture for current and new generation operators. It aims to eliminate complexity and cost, dramatically reduce new service deployment time, and lay the foundation for IMS in networks.

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs.  These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.

Powerlase Photonics Ltd is an innovative, independent, high power laser company, focused on powerful femtosecond, picosecond and nanosecond high energy Diode Pumped Solid State lasers. Powerlase Photonics Ltd has accelerated the introduction of high power lasers into a variety of industrial applications worldwide, primarily in materials processing, marking, annealing, and cleaning as well as other applications.  Customer-focused, and with an in-depth knowledge of applications, Powerlase Photonics Ltd enjoys significant expertise in designing and developing state-of-the-art process solutions for flat panel displays, photovoltaic, microelectronics, EUV, machine tool, automotive, and aerospace markets.

Within the Phoenix Contact group, Phoenix Contact Cyber Security AG is the competence center for industrial cyber security. The company emerged from the Innominate Security Technologies AG who pioneered industrial firewalls and created the mGuard product and solutions portfolio.  Phoenix Contact Cyber Security designs and develops innovative technologies which enable secure communication in manufacturing and process automation. More than one thousand customers already place their trust in the mGuard technology to protect themselves from cyber risks. These risks arise from the increasing interconnectedness and automation in manufacturing and along the entire value chain. Besides technology and product development, the company offers highly scalable global cloud systems for industrial applications. Furthermore, we actively support industrial companies by offering technical consulting services.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer.  Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself.  The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen.

Hyperwave is a leading provider of content management solutions with a focus on document and knowledge management in intranet environments.  Hyperwave solutions help companies bring greater efficiency to their decision-making processes, make decisions traceable, and communicate them faster.  The intranet as a central knowledge database plays an essential role in this process. Documents can easily be created and the associated business processes quickly started. Worldwide, more than 100 customers with more than 300,000 users in the public and private sectors have chosen Hyperwave as a strategic partner

OniX Microsystems designs, develops, and supplies micro-electro-mechanical systems (MEMS)-based all-optical switching engines for telecommunications equipment suppliers. Its products cover optical switching needs, including network protection and provisioning, optical add and drop multiplexing, and optical cross connects. It also offers MEMS design and photonic packaging services.  OniX Microsystems was founded in 1998 and was headquartered in Richmond, California.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

BigMachines is the global leader in enabling B2B sales, helping companies sell more and sell faster. BigMachines' award-winning on-demand configurator, pricing and quoting, proposal generator, and B2B eCommerce software solutions empower sales across customers' channels by streamlining their sales processes from opportunity to order. Using BigMachines software, sales teams and channels can quickly configure products, generate quotes and proposals, manage complex pricing, generate legal contracts, and manage orders. BigMachines offers extensive reporting capabilities and easily integrates to leading CRM and ERP systems, including those from salesforce.com, Oracle, Microsoft and SAP. BigMachines' rapidly growing customer base includes global leaders such as Kodak's GCG, Siemens, Ingersoll Rand, and NTT Communications, as well as innovative growth companies such as Acme Packet and Voltaire.

End2End is a provider of outsourced mobile data solutions in Europe. End2End’s managed service solutions are currently powering the delivery of mobile data services and content across more than 50 mobile operators in 20 countries on five continents.

DVC Deutsche Venture Capital, a venture capitalist based in Munich, focuses primarily on European growth companies in the areas of information, telecommunication, semiconductor and industrial technologies as well as life sciences. In the field of life sciences DVC invests in the development of therapeutic and diagnostic products as well as in platform and medical technologies. DVC’s total administrated fund volume amounts to 300 million Euro. For investments in private companies, DVC invests approximately 1 - 10 million Euro as lead investor or, in the case of larger financing rounds, as co-lead investor. DVC is a “value-added” financial investor. Each sector team consists of experienced investment managers with relevant backgrounds. Since its formation in 1998, DVC has invested in approximately 70 companies.

Deutsche Venture Capital

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless